Vitamin E (Tocopherols + Tocotrienols) · Evidence-First Fact Sheet

Quick Summary (60-second read)

Vitamin E is not one molecule — it is a family of eight chemically related compounds: four tocopherols (α, β, γ, δ) and four tocotrienols (α, β, γ, δ). All eight occur naturally in food, all eight can carry a "vitamin E" label on a supplement bottle, but they differ substantially in chemistry, bioavailability, tissue retention, and clinical evidence.

• α-tocopherol is the form the human body preferentially retains. A liver protein called α-tocopherol transfer protein (α-TTP) selectively loads α-tocopherol — especially the natural RRR stereoisomer — into circulating lipoproteins and delivers it to tissues. The other seven vitamin E compounds are metabolized and excreted comparatively quickly.
• The Recommended Dietary Allowance (15 mg/day for adults) refers only to α-tocopherol. The other forms (β-, γ-, δ-tocopherols; the four tocotrienols) have their own biology and their own emerging evidence base, but they are not counted toward the RDA.
• The upper-intake limit is in active regulatory transition. The U.S. Institute of Medicine sets it at 1,000 mg/day of α-tocopherol; the European Food Safety Authority lowered it to 300 mg/day in 2024, based on new meta-analytic signals for mortality and bleeding. Brazil (ANVISA) currently aligns with the IOM figure.

What the human-evidence record actually shows:

• Cardiovascular event prevention — primarily negative. Three large randomized trials (HOPE, n=9,541; HOPE-TOO, n=3,994 long-term; PHS II, n=14,641) all found no reduction in major cardiovascular events from vitamin E supplementation. HOPE-TOO observed a small increase in heart-failure hospitalizations; PHS II observed a increase in hemorrhagic stroke. Current expert consensus does not recommend vitamin E for cardiovascular disease prevention.
• Cancer prevention — primarily negative, with a notable harm signal in healthy men. The SELECT trial (Klein 2011, n=35,533) found that 400 IU/day of synthetic vitamin E was associated with a 17% relative increase in prostate cancer in healthy men over a median 7 years of follow-up. Earlier hints of a prostate-cancer benefit in the ATBC trial (1994) were not replicated.
• All-cause mortality — small but consistent signal at high doses. A meta-analysis of 19 randomized trials (Miller 2005) reported that supplemental vitamin E at ≥400 IU/day was associated with a modest increase in all-cause mortality.
• Non-alcoholic steatohepatitis (NASH) — the strongest positive hard-endpoint trial in vitamin E's history. In the PIVENS trial (Sanyal 2010, n=247 non-diabetic adults with biopsy-proven NASH), 800 IU/day of natural vitamin E for 96 weeks improved liver histology. This is a prescription-level use under medical supervision — not a general-wellness recommendation.
• Alzheimer's disease — one positive trial on functional decline (not cognition), in already-diagnosed patients. The TEAM-AD trial (Dysken 2014, n=613) showed that 2,000 IU/day of α-tocopherol slowed decline in activities of daily living by about 19% per year in patients with mild-to-moderate Alzheimer's. Cognition itself was not preserved. The dose exceeds the upper limit and requires medical supervision. Cochrane's systematic review (Farina 2017) concludes there is no convincing evidence that vitamin E prevents dementia or improves cognition in healthy or mildly impaired populations.
• AVED (Ataxia with Vitamin E Deficiency) — a rare genetic disease where vitamin E is the actual treatment. Mutations in the TTPA gene knock out α-TTP function. High-dose α-tocopherol (800–2,000 mg/day, under specialist supervision) can almost completely halt disease progression.
• AREDS / AREDS2 (age-related macular degeneration) — vitamin E (400 IU synthetic) is part of the multi-nutrient AREDS formula shown to slow advanced AMD; it has not been tested as a stand-alone intervention.
• Topical vitamin E for scars — not supported. A classic randomized trial (Baumann 1999) found that topical vitamin E did not improve scar appearance and caused contact dermatitis in roughly one-third of users.

General-adult intake guidance: Most public-health bodies endorse meeting the 15 mg/day RDA primarily through food — nuts, seeds, vegetable oils, leafy greens, and fortified foods. If a supplement is used, current evidence favors a daily dose at or below 200 mg/day of α-tocopherol (well above the RDA, well below the dose ranges associated with mortality and bleeding signals). High-dose vitamin E (≥400 IU/day) should not be self-administered for long periods. Specific therapeutic uses (NASH, diagnosed Alzheimer's, AVED) belong under medical supervision.

Bottom line for the casual reader: Vitamin E is genuinely essential — but its benefits as a supplement are narrower, more specific, and more form-dependent than its public reputation suggests. Several decades of large randomized trials have replaced the "antioxidant cures everything" narrative with a more measured picture: get the RDA from food, use modest supplements only if needed, and reserve high-dose vitamin E for documented medical indications under professional care.

What is Vitamin E? Chemistry, the eight-compound family, and the α-TTP gatekeeper

Eight chemicals, not one molecule

The term vitamin E covers eight naturally occurring fat-soluble compounds. All share a chromanol ring (a six-membered oxygen-containing ring fused to a benzene ring) attached to a 16-carbon isoprenoid side chain. They divide into two sub-families based on the saturation of that side chain:

Within each sub-family, the four isomers differ in the methylation pattern on the chromanol ring:

• α — 5,7,8-trimethyl (the most highly methylated)
• β — 5,8-dimethyl
• γ — 7,8-dimethyl (the unmethylated C5 position gives γ-tocopherol unique reactive-nitrogen-species scavenging chemistry — see Mechanism)
• δ — 8-monomethyl (the least methylated; tends to have the strongest direct anti-inflammatory chemistry)

α-TTP: the liver protein that decides which vitamin E reaches your tissues

The reason vitamin E behaves, in practice, almost as if it were a single nutrient — α-tocopherol — is a small liver protein called α-tocopherol transfer protein (α-TTP), encoded by the TTPA gene. α-TTP selectively binds α-tocopherol (with strong preference for the natural RRR stereoisomer) and loads it onto very-low-density lipoprotein (VLDL) particles for delivery throughout the body — brain, heart, liver, adrenal glands, gonads, skeletal muscle, and skin.

The other seven vitamin E compounds — β-, γ-, δ-tocopherol and the four tocotrienols — are not efficiently retained. They are metabolized by hepatic CYP4F2 (ω-hydroxylation) into water-soluble carboxyethyl-hydroxychroman (CEHC) metabolites and excreted in the urine. As a result, even when γ-tocopherol intake is two to three times higher than α-tocopherol intake (which is typical of Western diets, because soybean and corn oils are γ-dominant), plasma α-tocopherol concentrations typically run 6–15 µmol/L while plasma γ-tocopherol concentrations sit at only 1–3 µmol/L.

Three consequences follow directly from α-TTP biology:

1. The RDA addresses α-tocopherol because it is the form the body retains.
2. Mutations that disable α-TTP cause a real human disease — AVED (Ataxia with Vitamin E Deficiency, see Benefits §AVED) — where high-dose oral α-tocopherol is the disease-modifying treatment.
3. Tocotrienols, γ-tocopherol, and δ-tocopherol have their own emerging biology, but their plasma half-lives are short and their tissue saturation is low; product positioning that treats them as interchangeable with α-tocopherol is biologically incorrect.

The Recommended Dietary Allowance — and why it covers only α-tocopherol

Source: U.S. Institute of Medicine, Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids (2000); adopted in similar form by the NIH Office of Dietary Supplements and by the Chinese DRIs (with minor age-banding differences).

Upper Intake Limit — a regulatory landscape in transition

The EFSA 2024 downward revision represents the most significant regulatory shift on vitamin E in two decades. Readers should expect other jurisdictions to revisit their upper limits over the coming years. At doses above 300 mg/day of α-tocopherol, the safety margin is now considered narrower than once thought.

International Units (IU) to milligrams (mg) — the FDA 2018/2020 conversion

For decades, vitamin E was labeled in International Units. The U.S. Food and Drug Administration's 2018 Final Rule mandated conversion to milligrams of α-tocopherol on Nutrition and Supplement Facts labels effective 2020. Many existing products and most older literature still use IU, so the conversion is important:

The roughly two-fold difference in biological activity per milligram reflects α-TTP biology. The natural form (RRR-α-tocopherol) is one of two 2R stereoisomers that α-TTP recognizes most strongly. Synthetic all-rac-α-tocopherol contains eight stereoisomers — only four of which (the 2R group: RRR, RRS, RSR, RSS) are well retained. The four 2S stereoisomers (SRR, SRS, SSR, SSS) are rapidly metabolized and excreted. So an identical "mg on the label" of synthetic vitamin E delivers about half the long-term plasma and tissue α-tocopherol of natural vitamin E.

"α-tocopherol equivalents" — and when γ-, δ-, and tocotrienol forms matter

Historic vitamin E counting (α-tocopherol equivalents, α-TE) only credits the other forms partially: β-tocopherol at 50%, γ-tocopherol at 10%, α-tocotrienol at 30%, with β-, γ-, δ-tocotrienol and δ-tocopherol counted at essentially zero. This reflects their poor α-TTP retention. The convention is still in use in some food-composition databases.

That said, the other forms are not biologically inert — they simply do not contribute to the "vitamin E" pool that α-TTP polices. γ-Tocopherol has reactive-nitrogen-species scavenging activity that α-tocopherol does not. Tocotrienols ubiquitinate HMG-CoA reductase by a mechanism independent of statins. δ-Tocopherol has stronger NF-κB suppression than α. These are areas of ongoing research, and they are the reason mixed-tocopherol and tocotrienol products exist on the market alongside pure α-tocopherol. The clinical evidence for them is separate, smaller, and largely cluster-specific (lipids, NAFLD, bone, neurological signaling). See the dedicated Tocopherols and Tocotrienols sub-pages.

Mechanism of Action

Vitamin E's biological actions can be grouped into five mechanistic families. Some are shared by the whole eight-compound family; others are restricted to a specific sub-form.

1 · Chain-breaking lipid antioxidant (shared, but with quantitative differences). The chromanol ring's C6 hydroxyl group donates a hydrogen atom to lipid peroxyl radicals (LOO·), terminating the radical chain reaction of lipid peroxidation in membranes and lipoproteins. The resulting tocopheroxyl radical is comparatively stable and can be regenerated to active vitamin E by vitamin C, glutathione, and ubiquinol (CoQ10H₂). This is the textbook mechanism that explains vitamin E's role in protecting cell membranes, LDL particles, and the polyunsaturated fatty acids of the central nervous system from oxidative damage. All eight forms have this chemistry, but reaction kinetics vary: tocotrienols may distribute more broadly through membranes because of their unsaturated side chain; δ-tocopherol and δ-tocotrienol have the most chemically reactive hydroxyl groups.

2 · α-TTP-mediated tissue delivery (α-tocopherol only). As described in the Overview section, α-TTP selectively retains α-tocopherol — particularly the natural RRR stereoisomer — and delivers it via VLDL throughout the body. This is the mechanism that singles α-tocopherol out among the eight forms and is the biological basis for the RDA.

3 · γ-tocopherol's unique reactive-nitrogen scavenging. Because the C5 position of the γ-tocopherol chromanol ring is unmethylated, γ-tocopherol can directly trap peroxynitrite (ONOO⁻) and nitrogen dioxide radical (NO₂·) — reactive nitrogen species implicated in chronic inflammation, atherosclerosis, and certain types of nerve injury. The product 5-nitro-γ-tocopherol can be measured in human plasma and serves as a biomarker of in vivo nitrative stress. α-Tocopherol lacks this chemistry because its C5 is methylated. This is the molecular basis for the argument that mixed tocopherols — which include γ — provide antioxidant coverage that pure α-tocopherol does not.

4 · Non-antioxidant signaling pathways. Vitamin E modulates several signaling systems independently of free-radical chemistry:

• Protein kinase C-α (PKC-α) inhibition by α-tocopherol contributes to suppression of vascular smooth-muscle proliferation, platelet aggregation, and monocyte reactive-oxygen-species production.
• NF-κB / COX-2 / 5-LOX suppression is stronger with γ-tocopherol and the tocotrienols than with α-tocopherol; the downstream result is reduced prostaglandin E₂ and leukotriene B₄ production — a molecular basis for anti-inflammatory effects.
• HMG-CoA reductase ubiquitination and proteasomal degradation is a tocotrienol-specific mechanism (especially δ- and γ-tocotrienol) that lowers hepatic cholesterol synthesis. This is mechanistically distinct from statin therapy (which competitively inhibits the enzyme rather than degrading it).
• Nrf2 / ARE activation upregulates endogenous antioxidant enzymes (superoxide dismutase, glutathione peroxidase, heme oxygenase-1).
• mTORC1 modulation and autophagy induction have been described in cell culture for δ-tocotrienol.

5 · Vitamin K cycle interference. At high supplemental doses (typically ≥400 IU/day), α-tocopherol mildly inhibits the vitamin K-dependent γ-carboxylation of clotting factors II, VII, IX, and X. This is the biochemical basis for the bleeding-risk signal observed in the PHS II trial (increased hemorrhagic stroke; see Benefits §Cardiovascular) and for clinical recommendations to stop high-dose vitamin E approximately two weeks before elective surgery and to use caution alongside anticoagulant or antiplatelet medication.

Strength of mechanistic evidence: Lipid-peroxidation chain-breaking and α-TTP-mediated tissue retention are textbook consensus. γ-Tocopherol's RNS scavenging and tocotrienol HMG-CoA reductase degradation are well-established at the chemistry and cell-biology level but with comparatively limited large-RCT translation. The non-antioxidant signaling pathways (PKC, NF-κB, Nrf2) have substantial in-vitro and animal support but variable human-biomarker and clinical-endpoint translation — the gap between mechanism and outcome is the central tension in the vitamin E evidence base.

Evidence-Based Benefits

The vitamin E evidence record is large, mature, and — among the most-studied supplements in nutritional science — contains an unusual concentration of large negative or null randomized trials alongside its positive findings. This section presents both. Each sub-section indicates evidence tier (A = strong/consistent, B = moderate, C = preliminary), the strongest individual studies (with PubMed PMIDs), and important limitations.

Dosage by Context

Key upper-intake limits (must be considered together):

Practical dosing rules of thumb:

• The RDA is a deficiency-prevention target, not an optimal antioxidant dose; there is no consensus "optimal" dose above the RDA.
• Once you cross 400 IU/day (about 270 mg α-tocopherol), you enter the dose range studied by Miller 2005, SELECT, PHS II, and HOPE-TOO — where small but real signals for mortality, prostate cancer (in healthy men), hemorrhagic stroke, and heart failure have been reported.
• Therapeutic high-dose regimens (PIVENS NASH at 800 IU, TEAM-AD Alzheimer's at 2,000 IU, AVED at 800–2,000 mg) belong to medical care, not general supplementation.
• Convert International Units to milligrams as needed: 1 mg α-tocopherol = 1.49 IU natural = 2.22 IU synthetic (FDA 2018 Final Rule).
• A mixed-tocopherol product (containing α plus γ and δ in proportions closer to dietary vitamin E) is, in theory, closer to the food matrix than pure α. The direct trial evidence for mixed tocopherols versus pure α at clinical endpoints is limited; reasonable consensus is to choose ≤ 200 mg α-tocopherol equivalents if a supplement is used.

Safety, Side Effects, Drug Interactions, and Special Populations

Forms of Vitamin E Compared

Natural (d-α) versus synthetic (dl-α) α-tocopherol — the most consequential consumer choice

The roughly two-fold bioavailability difference between natural and synthetic α-tocopherol explains why the U.S. FDA's 2018 Final Rule established the equivalence 1 mg natural d-α-tocopherol = 2 mg synthetic all-rac-α-tocopherol for labeling biological activity. It also explains why an old-label "400 IU" of natural vitamin E (≈ 268 mg) and an old-label "400 IU" of synthetic vitamin E (≈ 180 mg) deliver substantially different plasma α-tocopherol over time.

Mixed tocopherols (α + β + γ + δ)

Mixed tocopherol products are obtained as by-products of vegetable-oil refining (soybean, corn, sunflower distillates), typically with γ ≫ α > δ > β proportions — reflecting the natural ratios of those source oils. They appeal to consumers who want a vitamin E profile closer to the dietary matrix than pure α-tocopherol provides.

Advantages: include γ-tocopherol (with its reactive-nitrogen-species scavenging chemistry that α-tocopherol lacks) and δ-tocopherol (the most directly anti-inflammatory tocopherol on biochemistry); more closely approximate the vitamin E pattern in whole foods.

Caveats: still counted in α-tocopherol equivalents for RDA and upper-limit purposes; direct randomized-trial evidence for mixed tocopherols at clinical endpoints is limited compared with α-tocopherol alone; high-dose α-tocopherol can suppress plasma γ-tocopherol — so a high-α product may inadvertently reduce the γ-tocopherol benefit it is sometimes marketed for.

Tocopherols (see Tocopherols sub-page for full detail)

The four tocopherols (α, β, γ, δ) constitute the traditional and quantitatively dominant face of dietary vitamin E. The dedicated Tocopherols sub-page covers: the natural-versus-synthetic comparison in depth, IU-to-mg conversion in detail, the cluster of cardiovascular negative trials, the PIVENS NASH evidence, the TEAM-AD Alzheimer's functional trial, mixed-tocopherol product positioning, and the γ-tocopherol RNS-scavenging biology in particular.

Anchor: asxan.ai/ingredients/tocopherols/ (D5 #17 sub-page).

Tocotrienols (see Tocotrienols sub-page for full detail)

The four tocotrienols (α, β, γ, δ) are a chemically distinct sub-class with separate biology and a separate (and smaller) clinical evidence base. Sources include palm oil, rice bran, barley, and — uniquely — annatto seed, the only commercially significant source that is essentially δ-tocotrienol with a small γ-tocotrienol contribution and no α-tocopherol (so tocotrienol products derived from annatto avoid the suppression-of-T3 problem that occurs when α-tocopherol is present in significant amounts).

Distinctive mechanisms (covered in depth on the sub-page): HMG-CoA reductase ubiquitination and proteasomal degradation (lowering hepatic cholesterol synthesis by a mechanism independent of statin competitive inhibition); strong NF-κB suppression (δ > γ ≫ α); broad membrane distribution by virtue of the unsaturated farnesyl side chain.

Evidence clusters: lipids (Qureshi 2002, PMID 11882333; Daud 2013, PMID 24348043); non-alcoholic fatty liver (Pervez 2020, PMID 32951743); postmenopausal bone health (Shen 2018, PMID 29954374); platelet and stroke biology (Slivka 2020, PMID 32686874); inflammation and oxidative stress (Khor 2021, PMID 34297765).

Typical clinical-trial doses: 50–300 mg/day, most commonly using annatto-derived high-concentration δ-tocotrienol preparations.

Anchor: asxan.ai/ingredients/tocotrienols/ (D5 #18 sub-page).

Reading a vitamin E label — quick guidance

• Check the form. "d-α-tocopherol" or "RRR-α-tocopherol" = natural. "dl-α-tocopherol" or "all-rac-α-tocopherol" = synthetic. "Mixed tocopherols" should list the α, β, γ, δ breakdown. "Tocotrienols" is a separate sub-class.
• Check the milligrams of α-tocopherol equivalents, not just IU on older labels. The FDA 2018 Final Rule mandates milligrams on U.S. labels; many international products still use IU (1 mg α-tocopherol = 1.49 IU natural = 2.22 IU synthetic).
• Check the dose against the upper limit. EFSA 2024 (300 mg α-tocopherol/day) is more conservative than IOM (1,000 mg/day); products in the 200–400 mg/day range require some justification beyond "more is better."
• Check for third-party quality certification (USP Verified, NSF Contents Certified, or equivalent), particularly for high-dose products.
• Esterified forms (acetate, succinate) are generally preferred for shelf stability; bioavailability is comparable to free α-tocopherol after intestinal hydrolysis.

Vitamin E and Other Antioxidants — How It Fits in the Network

Vitamin E does not act in isolation. Several other antioxidant systems regenerate vitamin E, compensate for what it cannot do, or compete with it for the same biological roles. A page-level understanding of vitamin E is incomplete without the network context.

Synthesis: Vitamin E is one component of a network. The disappointing results of isolated high-dose vitamin E in cardiovascular, cancer, and cognitive trials are partially explained by the fact that nutrients in food come embedded in a network of co-acting antioxidants and other phytochemicals. The page-level recommendation aligns with mainstream consensus: get vitamin E primarily from food, where it co-occurs with vitamin C, carotenoids, polyphenols, fiber, and other supportive nutrients; reserve high-dose vitamin E for documented medical indications.

Cluster Sub-pages

This cluster hub covers vitamin E at an overview level. Two dedicated sub-pages provide deeper detail for each of the two sub-families:

• Tocopherols — the four-tocopherol sub-family in depth; natural vs synthetic; IU-to-mg conversion; cardiovascular negative-trial cluster; PIVENS NASH; TEAM-AD Alzheimer's; mixed-tocopherol product positioning; γ-tocopherol RNS-scavenging biology. (D5 #17 sub-page, launching in cluster.)
• Tocotrienols — the four-tocotrienol sub-family in depth; annatto, palm, rice-bran sources; HMG-CoA reductase ubiquitination biology; α-tocopherol competition with tocotrienol transport; lipids / NAFLD / bone / stroke evidence; regulatory landscape across U.S., E.U., China, and Brazil. (D5 #18 sub-page, launching in cluster.)

Frequently Asked Questions

The questions below are the most-searched questions on vitamin E across general web search and AI assistants. Answers reflect the evidence cited throughout this page and are intentionally concise; deeper detail lives in the relevant sections above.

Tags

Body Systems: Cardiovascular · Neurological & Cognitive · Skin & Connective Tissue · Immune System · Liver & Detoxification

Mechanisms: Free radical scavenging · α-TTP-mediated tissue delivery · γ-tocopherol reactive nitrogen species (RNS) scavenging · PKC-α inhibition · NF-κB signaling inhibition · HMG-CoA reductase ubiquitination and degradation · NRF2 activation · Vitamin K cycle interference

Evidence Tier: Meta-analysis supported

Dosage Range: RDA 15 mg/d α-tocopherol (food first) · general-wellness supplement ≤200 mg/d · NASH 800 IU/d (physician) · AD 2,000 IU/d (physician) · AVED 800-2,000 mg/d (specialist) · EFSA 2024 UL 300 mg/d · IOM UL 1,000 mg/d

Last Evidence Review: 2026-05-24 · Reviewed by Evidence Synthesis Lead + Regulatory Compliance Lead

Related Goals

• heart-health
• cognitive-support
• longevity-stack
• inflammation-relief
• liver-health
• eye-protection

Related Lifestyles

• senior-60-plus
• plant-based
• pregnancy
• metabolic-syndrome

Related Ingredients

• tocopherols
• tocotrienols
• vitamin-c
• coq10
• astaxanthin
• selenium
• omega-3

References

All PMIDs verified by upstream evidence document (2026-05-24). Effect sizes are reported as published.

1. PMID 10639540 · Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P (HOPE Investigators). 2000. Vitamin E supplementation and cardiovascular events in high-risk patients. New England Journal of Medicine 342:154–160.
2. PMID 21990298 · Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, et al. 2011. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306(14):1549–1556.
3. PMID 15537682 · Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. 2005. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine 142(1):37–46.
4. PMID 23644932 · Age-Related Eye Disease Study 2 (AREDS2) Research Group. 2013. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA 309(19):2005–2015.
5. PMID 20427778 · Sanyal AJ, Chalasani N, Kowdley KV, et al (NASH CRN). 2010. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS). New England Journal of Medicine 362(18):1675–1685.
6. PMID 15769967 · Lonn E, Bosch J, Yusuf S, et al (HOPE and HOPE-TOO Investigators). 2005. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293(11):1338–1347.
7. PMID 18997197 · Sesso HD, Buring JE, Christen WG, Kurth T, et al. 2008. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 300(18):2123–2133.
8. PMID 28128435 · Farina N, Llewellyn D, Isaac MG, Tabet N. 2017. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database of Systematic Reviews CD002854.pub5.
9. PMID 8127329 · The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. 1994. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New England Journal of Medicine 330(15):1029–1035.
10. PMID 24381967 · Dysken MW, Sano M, Asthana S, Vertrees JE, et al (TEAM-AD VA Cooperative Trial). 2014. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 311(1):33–44.

Additional Cited References (cluster context)

• PMID 10417589 · Baumann LS, Spencer J. 1999. The effects of topical vitamin E on the cosmetic appearance of scars. Dermatologic Surgery 25(4):311–315.
• PMID 19066368 · Gaziano JM, Glynn RJ, Christen WG, et al. 2009. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 301(1):52–62.
• PMID 31975502 · Rattanawiwatpong P et al. 2020. Anti-aging and brightening effects of a topical treatment containing vitamin C, vitamin E, and raspberry leaf cell culture extract.
• PMID 27757026 · Hemilä H. 2016. Vitamin E and pneumonia in older men.
• PMID 36029025 · Wang J et al. 2022. Effects of vitamin E on semen quality in infertile men: a systematic review and meta-analysis.
• PMID 3302248 · London RS et al. 1987. The effect of alpha-tocopherol on premenstrual symptomatology: a double-blind study.
• PMID 19614907 · Parsay S et al. 2009. Therapeutic effects of vitamin E on cyclic mastalgia.
• PMID 28736267 · Burbank AJ et al. 2018. Gamma tocopherol-enriched supplement reduces sputum eosinophilia and endotoxin-induced sputum neutrophilia in subjects with asthma.
• PMID 11882333 · Qureshi AA et al. 2002. Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran.
• PMID 32951743 · Pervez MA et al. 2020. Effects of delta-tocotrienol supplementation on liver enzymes, inflammation, oxidative stress and hepatic steatosis in non-alcoholic fatty liver disease.
• PMID 29954374 · Shen CL et al. 2018. Tocotrienol supplementation suppressed bone resorption and oxidative stress in postmenopausal osteopenic women.
• PMID 36689199 · Gu 2023. NASH network meta-analysis (PIVENS reinforcement).
• PMID 39412049 · Wen 2024. Cochrane NASH/MASH systematic review.
• PMID 39970876 · Song 2025. Multicenter Chinese MASH RCT.
• GeneReviews chapter on AVED (NCBI Bookshelf NBK1241).

Regulatory and Reference Sources

• NIH Office of Dietary Supplements · Vitamin E Fact Sheet for Health Professionals
• U.S. FDA 2018 Final Rule on Converting Units of Measure for Folate, Niacin, and Vitamins A, D, and E (mg α-tocopherol labeling)
• EFSA 2024 Scientific Opinion on the tolerable upper intake level for vitamin E (EFSA Journal 2024;22:8953) — UL revised to 300 mg/day α-tocopherol
• EU Regulation 432/2012 — authorized health claim: "vitamin E contributes to the protection of cells from oxidative stress"
• IOM 2000 Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids (National Academies Press)
• AASLD 2018 and AGA 2023 guidelines on NAFLD / NASH management (include vitamin E 800 IU/day for biopsy-confirmed non-diabetic NASH)

Cross-link to Related ASXAN Pages

• Tocopherols (sub-page, D5 #17): depth on the four-tocopherol sub-family; natural-versus-synthetic in detail; IU-to-mg conversion; the cardiovascular negative-trial cluster; PIVENS NASH; TEAM-AD Alzheimer's; mixed-tocopherol product positioning; γ-tocopherol's reactive-nitrogen-species chemistry.
• Tocotrienols (sub-page, D5 #18): depth on the four-tocotrienol sub-family; annatto, palm, and rice-bran sources; HMG-CoA reductase ubiquitination biology; α-tocopherol competition with tocotrienol transport; lipids / NAFLD / bone / stroke evidence; regulatory landscape across U.S., E.U., China, and Brazil.
• Vitamin C (if published): water-soluble partner of vitamin E in the antioxidant recycling cascade.
• Coenzyme Q10 (if published): mitochondrial co-regenerator of vitamin E.
• Astaxanthin (D5 #1, published): carotenoid with stronger lipid-environment antioxidant chemistry than α-tocopherol; spans the lipid bilayer.
• Selenium (if published): glutathione-peroxidase cofactor and SELECT-trial co-tested nutrient.
• Omega-3 (D5 #4, published): vitamin E protects omega-3 polyunsaturated fatty acids in cell membranes from peroxidation; combined high-dose vitamin E and fish-oil supplementation compounds bleeding risk.

Educational Disclaimer

Educational reference page. Not medical advice. Specific therapeutic uses of vitamin E (NASH, diagnosed Alzheimer's disease, AVED, AREDS formula in advanced age-related macular degeneration, severe deficiency states) require diagnosis, dose selection, and follow-up by a qualified healthcare provider. Consult your physician before starting any high-dose supplement, particularly if you take anticoagulant or antiplatelet medication, are scheduled for surgery, are pregnant or lactating, or have a history of heart-rhythm disorders or hemorrhagic stroke.